| Author | Oliveira, Gabriel Melo de | |
| Author | Rossi, Maria Inês Doria | |
| Access date | 2020-07-10T19:07:56Z | |
| Available date | 2020-07-10T19:07:56Z | |
| Document date | 2020 | |
| Citation | OLIVEIRA, Gabriel Melo de; ROSSI, Maria Inês Doria. The possible management of hypertensive patients infected with COVID-19 through the use of Aliskiren. Nephrology and Renal Diseases, v. 5, p. 1-5, May 2020. | pt_BR |
| ISSN | 2399-908X | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/42205 | |
| Language | eng | pt_BR |
| Publisher | Scholars Central | pt_BR |
| Rights | open access | |
| Subject in Portuguese | COVID-19 | pt_BR |
| Subject in Portuguese | Pacientes hipertensos | pt_BR |
| Subject in Portuguese | Manejo | pt_BR |
| Subject in Portuguese | Infecção | pt_BR |
| Subject in Portuguese | Uso de Aliskiren | pt_BR |
| Title | The possible management of hypertensive patients infected with COVID-19 through the use of Aliskiren | pt_BR |
| Type | Article | |
| DOI | 10.15761/NRD.1000165 | |
| Abstract | In late 2019, a novel corona virus (COVID-19) was identified in Wuhan, a city in the Hubei province of China. COVID-19 rapidly spread and led to an outbreak
in China and then became a global health emergency. Human pathogenic coronavirus bind to their target cells through angiotensin-converting enzyme 2 (ACE2).
The expression of ACE2 is substantially increased in hypertension patients and with type 1 or type 2 diabetes. Hypertension is also treated with ACE inhibitors and
ARBs, which results in an upregulation of ACE2.We therefore hypothesis that hypertension and diabetes treatment with ACE2-stimulating drugs increases the risk
of developing severe and fatal COVID-19. Therefore, we propose for COVID-19 patients to prevent ANG I and II formation by direct blockade of renin with the
specific inhibitor called Aliskiren. The aliskiren acts as a renin inhibitor, which blocks the conversion of angiotensinogen to ANG I. Hence, blood pressure is reduce
by decreasing the amount of ANG II to reach the AT1 receptor, thereby causing a decrease ACE2 released. Through the respective review, we hope to contribute to
the treatment of patients infected with COVID-19, especially hypertensive patients. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Celular. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Ciência e Tecnologia em Biomodelos. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Subject | COVID-19 | pt_BR |
| Subject | Possible management | pt_BR |
| Subject | Hypertensive patients | pt_BR |
| Subject | Infection | pt_BR |
| Subject | Use of Aliskiren | pt_BR |
